SCHEMBL3402622

SCHEMBL3402622

CC(C)C[C@H](N)C(=O)OC(=O)[C@@H](N)CCC(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 2/20 0.48
GABRD O14764 2/20 0.48
GABRA1 P14867 2/20 0.48
GABRB1 P18505 2/20 0.48
GABRG2 P18507 2/20 0.48
GABRB3 P28472 2/20 0.48
GABRA5 P31644 2/20 0.48
GABRA3 P34903 2/20 0.48
GABRA2 P47869 2/20 0.48
GABRB2 P47870 2/20 0.48
GABRA4 P48169 2/20 0.48
GABRE P78334 2/20 0.48
GABRA6 Q16445 2/20 0.48
GABRG1 Q8N1C3 2/20 0.48
GABRG3 Q99928 2/20 0.48
GABRQ Q9UN88 2/20 0.48
CYP1A2 P05177 2/20 0.48
SLC1A3 P43003 2/20 0.48
SLC1A2 P43004 2/20 0.48
SLC7A5 Q01650 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29564893 0.89 GABRP (0.48) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL4959221 0.87 GRM8 (0.62) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL496858 0.87 GRM8 (0.62) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL1537429 0.86 SLC7A5 (0.44) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2695665 0.86 ALOX15 (0.47) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL12497981 0.86 ALOX15 (0.47) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL3402553 0.85 GABRP (0.52) GABRPGABRDGABRA1GABRB1GABRG2
Hydrochloric Acid SCHEMBL10636419 0.85 GRM8 (0.60) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL995721 0.84 SLC7A5 (0.58) SLC1A3SLC1A2SLC7A5SLC1A1DPP4
SCHEMBL9100153 0.84 SLC7A5 (0.58) SLC1A3SLC1A2SLC7A5SLC1A1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122045749-A Method for identifying key flavor substances of rice based on materially group science and machine learning 华中农业大学 2026-05-15 CN disclosed
US-20250000364-A1 GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS GLAS USA LLC 2025-01-02 US disclosed
US-12089916-B2 Gastrointestinal tract detection methods, devices and systems BIORA THERAPEUTICS, INC. (US) 2024-09-17 US disclosed
EP-4252629-A2 GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS Biora Therapeutics, Inc. (US) 2023-10-04 EP disclosed
EP-3551046-B1 GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS BIORA THERAPEUTICS INC (US) 2023-07-19 EP disclosed
US-20230009902-A1 TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM GLAS USA LLC 2023-01-12 US disclosed
US-11547301-B2 Methods for collecting and testing bacteria containing samples from within the gastrointestinal tract BIORA THERAPEUTICS, INC. (US) 2023-01-10 US disclosed
US-20220273196-A1 INGESTIBLE DEVICE AND ASSOCIATED METHODS GLAS USA LLC 2022-09-01 US disclosed
CN-114269951-A Diagnostic method for aesthetic deterioration of skin 欧莱雅 2022-04-01 CN disclosed
US-11224364-B2 Ingestible device and associated methods PROGENITY, INC. (US) 2022-01-18 US disclosed
WO-2018106945-A1 GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS PROGENITY INC. (US) 2018-06-14 WO disclosed
US-9977034-B2 Biomarkers for fatty liver disease and methods using the same Meabolon, Inc. (US) 2018-05-22 US disclosed
US-20150377910-A1 Biomarkers for Fatty Liver Disease and Methods Using the Same METABOLON, INC. 2015-12-31 US disclosed
US-20100279956-A1 Biomarkers For Fatty Liver Disease And Methods Using The Same METABOLON, INC. 2010-11-04 US disclosed
EP-2225386-A2 PROCESS FOR THE ENZYMATIC PREPARATION OF A GAMMA-GLUTAMYL COMPOUND Unilever PLC (GB) 2010-09-08 EP disclosed
WO-2009083454-A2 PROCESS FOR THE ENZYMATIC PREPARATION OF A GAMMA-GLUTAMYL COMPOUND UNILEVER PLC (GB) 2009-07-09 WO disclosed
US-20090169704-A1 Process for the enzymatic preparation of a gamma-glutamyl compound CONOPCO, INC. D/B/A UNILEVER 2009-07-02 US disclosed
EP-0883629-A1 OLIGOPEPTIDES FOR DRUG DELIVERY Emisphere Technologies, Inc. (US) 1998-12-16 EP disclosed
WO-1997031938-A9 OLIGOPEPTIDES FOR DRUG DELIVERY 1997-11-20 WO disclosed
WO-1997031938-A1 OLIGOPEPTIDES FOR DRUG DELIVERY EMISPHERE TECHNOLOGIES, INC. (US) 1997-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12089916-B2 Gastrointestinal tract detection methods, devices and systems FABP2, SI, MLNR GABRP 3314/4885GABRD 2536/4885GABRA1 2930/4885
US-11547301-B2 Methods for collecting and testing bacteria containing samples from within the gastrointestinal tract SI, VIP, MLN GABRP 4505/4885GABRD 3520/4885GABRA1 4248/4885
US-20250000364-A1 GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS FABP2, SI, MLNR GABRP 3314/4885GABRD 2536/4885GABRA1 2930/4885
US-20230009902-A1 TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM ALPG, ALPP, FABP2 GABRP 4597/4885GABRD 3894/4885GABRA1 4208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.